Release issued 29th January 2008

29th January 2008, Godalming, UK: Sinclair Pharma plc ("Sinclair"), the international specialty pharmaceutical company, announces the EU registration of its pipeline product SPHR900 for herpes simplex, which causes recurring sores on the skin, lips or mouth, also known as cold sores.

SPHR900 is a proprietary topical treatment aimed at reducing the symptoms of herpes simplex cold sores and accelerating the healing process. The product forms an invisible film on the affected area and incorporates several plant-derived compounds which have been shown to inhibit the growth of the relevant herpes simplex viruses as well as reducing discomfort and inflammation.

Sinclair applied its expertise in topical and barrier formulations to develop SPHR900, which represents a new therapeutic area for the company. The product is registered as Medical Device Class IIa and can be sold without a prescription in the EU. Sinclair plans to commercialise the product through marketing partners in most countries.

The OTC market for herpes simplex products in the UK, France and Germany is valued at £83m. In Spain and Italy, products for cold sores are commonly prescribed, opening up a new sector of the market for Sinclair in these regions.

Dr Michael Flynn, CEO of Sinclair Pharma plc. commented: "SPHR900 is responding to a need in the market for an antiviral that can simultaneously reduce symptoms and act against the herpes virus. We believe SPHR900 will be an important addition to the company's product range and its commercialisation will contribute to our growing presence in the EU market."

(12th December 2007) Sinclair Pharma plc announces EU registration of new head lice treatment

(6th December 2007) Sinclair Pharma plc announces EU registration of new teething gel product, SPHO220

(16th October 2007) Sinclair Pharma plc announces US launch of Aloclair (Ameseal) oral lesion relief spray by OMNI Preventive Care, a 3M ESPE Company

(4th October 2007) Sinclair Pharma plc presents data for pipeline acne product SPHD420 at World Congress of Dermatology meeting

(27th September 2007) Sinclair Pharma plc announces Dr Reddy's Laboratories, Inc. as Sebclair marketing partner in US